Patents by Inventor Susannah D. Barbee

Susannah D. Barbee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-C-C CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230416382
    Abstract: This present invention provides anti-C—C chemokine type 8 (CCR8) antibodies and antigen binding fragments thereof, methods of making the antibodies or antigen binding fragments thereof, and methods of use thereof to bind to human CCR8 on CCR8 expressing cells, e.g., tumor-infiltrating Treg cells, to remove CCR8 expressing cells, e.g, tumor-infiltrating Treg cells, to reduce or inhibit tumor growth and/or to treat cancer.
    Type: Application
    Filed: October 13, 2021
    Publication date: December 28, 2023
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Susannah D. BARBEE, Shujun YUAN, Marcel MEURY, Alessandro PALUMBO, Terence WONG, Kathrin ZUBERBUHLER, Emilia FALKOWSKA
  • Methods of treatment with CD80 extracellular domain polypeptides
    Patent number: 11789010
    Abstract: This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 17, 2023
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, Barbara Sennino, Susannah D. Barbee, Ursula Jeffry
  • CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEINS FOR TREATING PD-L1 NEGATIVE TUMORS
    Publication number: 20220031806
    Abstract: The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).
    Type: Application
    Filed: February 21, 2020
    Publication date: February 3, 2022
    Inventors: Susannah D. BARBEE, Thomas BRENNAN, Barbara SENNINO
  • CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN DOSING REGIMENS
    Publication number: 20210340214
    Abstract: The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1) to a subject in need thereof, for example, a cancer patient.
    Type: Application
    Filed: August 28, 2019
    Publication date: November 4, 2021
    Inventors: Sandeep P. INAMDAR, Kristen PIERCE, Hong XIANG, Susannah D. BARBEE
  • METHODS OF TREATMENT WITH CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES
    Publication number: 20200182858
    Abstract: This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 11, 2020
    Inventors: Thomas BRENNAN, Barbara SENNINO, Susannah D. BARBEE, Ursula JEFFRY
  • COMBINATION THERAPY FOR CANCER USING ANTI-GITR ANTIBODIES
    Publication number: 20200031944
    Abstract: Provided herein are methods of treating cancer with a combination of an anti glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR)-antibody and an antibody that binds colony stimulating factor 1 receptor (CSF1R) or with a combination of an anti-GITR antibody and an antibody that binds programmed cell death protein 1 (PD-1).
    Type: Application
    Filed: March 29, 2018
    Publication date: January 30, 2020
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Susannah D. Barbee, David Bellovin, Luis Borges